Repare Therapeutics and Debiopharm announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC clinical trial investigating lunresertib in combination with Debio 0123. In this trial, Debiopharm and Repare seek to assess the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of this PKMYT1 and WEE1 inhibitor combination.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
Questions or Comments about the article? Write to editor@tipranks.com